This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Innovating CMC for Oligonucleotide and Peptide Therapeutics

Share this article

The task of developing oligonucleotide- and peptide-based therapeutic products faces unique challenges, making it difficult to meet regulatory requirements and scale production for commercialization. Due to their size and molecular complexity, peptides and oligos require special considerations along the way. Without innovation, CMC processes are likely to suffer additional strain from the ever-increasing demand in the market.

In this first edition of the new TIDES eBook Series, we explore ways in which chemistry, manufacturing and controls (CMC) can be optimized. The ebook includes:

  • Case study: Generating a SARS-CoV-2 Epitope Library, Conducted by Gyros Protein Technologies
  • CMC Approaches to Accelerate Peptide, Oligonucleotides and mRNA therapeutics Development
  • Partnering in the Oligonucleotide and Peptide Therapeutics Industry
  • How AI Could Revolutionize Chemistry
  • Q&A With Ajinomoto Biopharma Services: Partnering with the Right CDMO

Click the image at the top of the page or here to begin exploring the ebook.

 

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Virtual Scientific Forum

02 - 05 Mar 2021
Industry leaders and service providers share cutting-edge content and company expertise across the Oligonucleotide, Peptide, mRNA and Drug Delivery spectrum
Go to site